AnitaB.org Welcomes New Executives to Achieve Ambitious Goal of 50/50 Tech Equity by 2025
Today, global nonprofit AnitaB.org announced that with its recent new hires it has fully staffed its Executive Team working on the ambitious goal of 50/50 intersectional tech equity by 2025. Three new hires join its executive bench to help achieve the company’s mission: Kety Maria Esquivel as Vice President of Marketing and Communications; Robert G. Read as Vice President, Business Development and Partnership Success; and Victoria Hughes as Vice President of People and Culture.
The three new appointees will join CEO and President Brenda Darden Wilkerson’s leadership team as the non-profit tech women’s organization looks to expand its global reach and continues to improve its roster of AnitaB.org/365 programs that help women and underrepresented communities gain access and career opportunity through technology.
Esquivel has been brought in to lead the world-wide marketing team, bringing more than two decades of global marketing and communications experience to the role. Prior to AnitaB.org, Esquivel led the marketing and communication efforts for top tier agencies, companies and nonprofits globally, most recently serving as an EVP for Edelman where she led the Consumer, Technology and Tourism teams. Read will lead AnitaB.org’s business development and partnerships teams, bringing more than 20 years of global experience in maximizing partnerships and driving media and entertainment technology solutions to the role. Prior to AnitaB.org, Read served as SVP at Universal Pictures in Los Angeles where he managed film and television content distribution across the globe. Hughes joins the organization to lead the global Human Resource (HR) team. With more than 20 years of HR experience, Hughes brings a focus on building a best-in-class culture. Previously, Hughes served as head of talent management at Delta Dental of California and head of talent solutions at Kaiser Permanente.
“We need the most ambitious, inventive and diverse leaders to propel us to global 50/50 intersectional tech equity by 2025,” said Wilkerson. “The unique backgrounds and combined experience these eleven individuals bring is remarkable. It’s an extremely powerful team who will not only drive the necessary change for AnitaB.org but also lead and inspire our partners, clients, and the tech industry holistically to achieve remarkable results.”
The new hires join an innovative bench of leaders that Brenda Darden Wilkerson has worked to assemble since she joined the company in 2017. A pioneer herself, Brenda founded the original Computer Science for All program, building computer science classes into the curriculum for every student in the Chicago Public Schools, which served as an inspiration for the Obama administration’s national CS4All initiatives. The full AnitaB.org Executive team includes:
- Dr. Jacqueline Bouvier Copeland, Chief Operating Officer, an award-winning global social impact executive, who has devoted her 30-year career to building high impact organizations that advance human rights and equity. Trained as a cultural anthropologist and urban designer, she has been recognized as a HistoryMaker by the US Congress for her leadership and created the initial design for the My Brother’s Keeper initiative, which was adopted by President Obama.
- Ylonda Davis, Vice President, Global Events and Customer Experience, a global events expert who has led strategic event management, customer marketing, end-user relations, partner marketing, and vendor management for Fortune 200 companies, including Apple, Intel, Symantec, VMware, and Marketo.
- Michelle Flatt, Vice President, Programs, a strong leader with a foundation in education having been an English teacher, a district-level leader, and most recently, a high-school Principal. Her work in education focused on interrupting the inequity that plagues communities of color.
- Maggie Inbamuthiah, Interim Managing Director, India, an entrepreneur who brings a deep technology background having worked across different departments including product vision and strategy, customer implementations, operations, business development, and marketing.
- Mary Kempski, Chief Information Officer, a seasoned technical leader who has led business operations, infrastructure, process improvement and application deployment at AnitaB.org for over three years and is responsible for strategic vision and execution of scalable systems and technology solutions.
- Jo Anne Lee, Chief Financial Officer, an experienced financial leader who has provided financial oversight to global business unit divisions and brings a unique understanding of established corporations as well as agile startup environments.
- Dr. Stephanie Rodriguez, Vice President of Policy & Engagement, an immunologist by training, who found her way to STEM education policy and advocacy through years of STEM-related community outreach, and service as a AAAS Science & Technology Policy Fellow at the National Science Foundation.
- DaWana Williamson, Innovation Lead, an engineer turned nonprofit operations executive with a proven ability to successfully lead, innovate, and scale programs and services in high growth environments.
The organization will host its annual Grace Hopper Celebration (GHC), the world's largest gathering of women technologists, in Orlando, Florida from October 1-4, attracting over 25,000 mostly women technologists from over 50 countries.
AnitaB.org is a nonprofit social enterprise committed to increasing the representation of women technologists in the global workforce. AnitaB.org engages with tens of thousands of women and leading organizations around the world to build diverse and inclusive workplace cultures. Founded in 1997 by our namesake, computer science visionary Anita Borg, and her co-founder and fellow computer scientist, Telle Whitney, our organization works toward a future where the teams that create technology mirror the people and societies for whom they build it.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Idriverplus Joins the “Automate with Velodyne” Ecosystem29.5.2020 21:31:00 EEST | Press release
Velodyne Lidar, Inc. and Idriverplus today announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. Through the program, Velodyne will further collaborate with Idriverplus to support its continued innovation and promote Idriverplus autonomous vehicles, including street cleaners, passenger cars and logistics vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200529005589/en/ Velodyne Lidar, Inc. and Idriverplus announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. (Photo: Velodyne Lidar) Recently, Velodyne signed a multi-year sales agreement with Idriverplus to provide Puck™ sensors for the mass production of autonomous vehicles. Idriverplu
Takeda to Present Data from the ICLUSIG® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML29.5.2020 15:00:00 EEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 56th American Society of Clinical Oncology (ASCO) Annual Meeting and the 25th European Hematology Association (EHA) Annual Meeting. The OPTIC trial is an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ICLUSIG® (ponatinib) over a range of three starting doses (45-, 30-, or 15-mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow-up of approximately 21 months, data from the interim analysis of OPTIC show that the optimal benefit-risk profile for ICLUSIG in patients with CP-CML is achieved with a daily starting dose of 45-mg and, upon achieving ≤1% BCR
Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings29.5.2020 15:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2. The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-r
Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks29.5.2020 15:00:00 EEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on a Type II Variation regulatory application and recommended the approval of a pre-filled syringe presentation of TAKHZYRO® (lanadelumab). TAKHZYRO is a subcutaneous injectable prescription medication approved in Europe for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat.1,2,3 “Our goal is to continuously innovate in all areas of HAE management,” said Isabel Kalofonos, Global Product Strategy Lead, HAE, Takeda. “This positive opinion marks another important step forward as we aim to enhance the experience of treatment administration for peo
Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS29.5.2020 15:00:00 EEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced the results of the Phase 2 Pevonedistat-2001 trial will be presented during oral sessions at the virtual 56th American Society of Clinical Oncology (ASCO) Annual Meeting and the virtual 25th European Hematology Association (EHA) Annual Meeting. The study evaluated pevonedistat plus azacitidine versus azacitidine alone in patients with rare leukemias, including higher-risk myelodysplastic syndromes (HR-MDS). These results show that the combination of pevonedistat and azacitidine is a highly active, promising therapeutic approach and suggest benefit in the HR-MDS subgroup across multiple clinically meaningful endpoints, including overall survival (OS), event-free survival (EFS), complete remission (CR) and transfusion independence, with a safety profile similar to azacitidine alone. The Pevonedistat-2001 trial was designed as a proof-of-concept study in patients with HR-MDS, higher-risk chronic myelomonocytic leuke
LetsGetChecked Debuts FDA EUA-Authorized At-Home Coronavirus (COVID-19) Sure-track Test29.5.2020 14:57:00 EEST | Press release
LetsGetChecked, the leading direct-to-consumer at-home health testing and insights company, announces today the authorization of the new Coronavirus (COVID-19) Sure-track Test for at-home consumer use by the U.S. Food and Drug Administration under an EUA. The new test is authorized to serve at-risk individuals with a proprietary at-home PCR nasal swab test that delivers accurate and definitive results within 24 hours. Offering an end-to-end model, LetsGetChecked’s new Sure-track Test introduces the most complete FDA EUA-authorized Coronavirus at-home testing solution. The at-home Coronavirus (COVID-19) test incorporates a nasal swab and PCR lab analysis, offering convenient and secure results in 24 hours. Unlike serology tests that detect the presence of antibodies, the at-home COVID-19 test determines the presence or absence of SARS-CoV-2 viral RNA. LetsGetChecked’s Sure-track Test is the only FDA EUA-authorized at-home Coronavirus (COVID-19) test that owns all aspects of the testing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom